Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
MannKind Corp. has cleared one of the shadows hanging over its experimental inhalable insulin product, announcing that it had reached an arbitration resolution with an employee who had accused the company of firing him after he alleged improprieties.
The Valencia biotech, which has faced several roadblocks to gaining U.S. regulatory approval of its Afrezza inhaler, said late Tuesday that both it and John Arditi, a former senior director for regulatory affairs, had agreed to drop complaints against each other.
Arditi in November 2010 filed a wrongful termination lawsuit against the company, claiming he was fired after his internal audits uncovered "potential fraud and scientific misconduct" involving Afrezza clinical trial data, according to the lawsuit. He claimed that the company did not inform the FDA about his findings for fear it would delay the drug?s approval.
http://www.labusinessjournal.com/news/2011/dec/14/mannkind-resolves-claims-former-employee/
The Valencia biotech, which has faced several roadblocks to gaining U.S. regulatory approval of its Afrezza inhaler, said late Tuesday that both it and John Arditi, a former senior director for regulatory affairs, had agreed to drop complaints against each other.
Arditi in November 2010 filed a wrongful termination lawsuit against the company, claiming he was fired after his internal audits uncovered "potential fraud and scientific misconduct" involving Afrezza clinical trial data, according to the lawsuit. He claimed that the company did not inform the FDA about his findings for fear it would delay the drug?s approval.
http://www.labusinessjournal.com/news/2011/dec/14/mannkind-resolves-claims-former-employee/